Related Research Articles
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.
John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.
CHI-California Healthcare Institute is a private, non-profit public policy research and advocacy organization, representing more than 250 universities, academic research centers, biotechnology, and medical device companies. Founded in 1993, and based in La Jolla, California, CHI has offices in Washington, D.C., and Sacramento, California. CHI publishes an annual California Biomedical Industry report, providing data on the scope and scale of academic and commercial life sciences research and development within the state. In 2008, the industry employed more than 270,000 Californians and produced revenues in excess of $75 billion.
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
Ivor Royston is an American oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.
Christoph Westphal is an American biomedical businessman.
Connect is a non-profit serving the San Diego and Southern California region. Connect elevates innovators and entrepreneurs throughout their growth journey by providing educational programming, mentorship, networking events, and access to capital. The current CEO is Mike Krenn.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Richard B. Hollis is the founder, chairman, and CEO of Holonis, Inc., a San Diego-based software company. Hollis had previously founded Hollis-Eden Pharmaceuticals, a San Diego-based pharmaceutical company, in 1994.
BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.
Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenix Inc., the company went public in 1992. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and forming partnerships to develop them further.
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
PDL BioPharma is a publicly traded American holding company that since 2008 manages patents and other intellectual property that had been generated by the company. In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million.
Kevin Donald Lustig is an American scientist and entrepreneur and founder of three life science companies: the pharmaceutical company Kalypsys in 2001; the online research marketplace Scientist.com in 2007; and the non-profit lab incubator Bio, Tech and Beyond in 2013.
3Scan, Inc. was an American biotechnology company based in San Francisco, California which was acquired in 2019, when 3Scan became a part of Strateos. It offered automated microscopy services using a coordinated combination of both hardware and software for the 3D analysis of cells, tissues, and organs. The company was founded in 2011 by Todd Huffman, Megan Klimen, Matthew Goodman, and Cody Daniel. The 3Scan technology is based on the Knife Edge Scanning Microscope developed in the late 1990s by Bruce McCormick, founder of the Brain Networks Lab at Texas A&M University.
James C. “Jim” Mullen is an American business executive. He is the executive chairman at genome editing company Editas Medicine since 2018, where he also served as CEO between 2021 and 2022. He was formerly the president and CEO of Biogen Idec until he retired effective June 8, 2010. At the same time, he started he would retire from the board at the end of his term. In 2011, he was named CEO to drug manufacturer Patheon, based in Durham, North Carolina, as well as to their board. He stayed there until August 29, 2017.
William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Entos, Inc.. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.
John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.
George A. Scangos was a pharmaceutical executive and former chief executive officer of Vir Biotechnology from 2017 to 2023. Scangos was previously the chief executive officer of Biogen from 2010 to 2016 and of Exelixis from 1996 to 2010. Prior to joining industry, Scangos was a professor of biology at Johns Hopkins University.
References
- ↑ "Forbes.com: Howard C. Birndorf". Forbes. Archived from the original on January 23, 2013. Retrieved 2010-01-30.
- ↑ "Howard Birndorf Interview". UC San Diego. 2008. Retrieved 2019-12-03.
- 1 2 3 Kramer, Mary (26 May 1997). "BIOTECH SUPERSTAR COULD PLANT HIS IDEAS HERE". Crain's Detroit Business. Retrieved 2020-09-22.
- ↑ Bigelow, Bruce (2011-11-16). "Xconomy: Nordhoff Retiring from Gen-Probe Board". Xconomy. Retrieved 2020-09-22.
- 1 2 Fikes, Bradley (2018-05-09). "San Diego's Hybritech still influences local biotech, 40 years later". San Diego Union-Tribune. Retrieved 2020-09-22.
- 1 2 Sterngold, James (1996-08-18). "The Johnny Appleseed of a Biotechnology Forest". The New York Times. ISSN 0362-4331 . Retrieved 2020-09-22.